Document is current
Any future updates will be listed below
-
Authors
Ogwel, Billy
Mzazi, Vincent H.
Awuor, Alex O.
Okonji, Caleb
Anyango, Raphael O.
Oreso, Caren
Ochieng, John B.
Munga, Stephen
Nasrin, Dilruba
Tickell, Kirkby D.
Pavlinac, Patricia B.
Kotloff, Karen L.
Omore, Richard
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (EFGH Rising star(grant INV-045988), EFGH Rising star(grant INV-045988), EFGH Rising star(grant INV-045988), EFGH Rising star(grant INV-045988), EFGH Rising star(grant INV-045988), EFGH Rising star(grant INV-045988), EFGH Rising star(grant INV-045988), EFGH Rising star(grant INV-045988), EFGH Rising star(grant INV-045988), EFGH Rising star(grant INV-045988), EFGH Rising star(grant INV-045988), EFGH Rising star(grant INV-045988))
- License Information
-
More Information
Article History
Received: 8 March 2024
Accepted: 22 November 2024
First Online: 2 December 2024
Declarations
:
: The VIDA protocol was approved by the Institutional Review Board of the University of Maryland School of Medicine, Baltimore, MD, USA (UMB Protocol #: HM-HP-00062472) and the Kenya Medical Research Institute (KEMRI) Scientific and Ethical Review Unit (SERU) (SERU#2996). The EFGH protocol was approved by the KEMRI SERU (SERU#4362). Written informed consent was sought from caregivers in both studies before initiation of study procedures. Additionally, ethical approval for undertaking the current study was sought from the health research ethics committee of the University of South Africa, College of Agricultural Sciences (2023/CAES_HREC/2192).
: Not applicable.
: The authors declare no competing interests.
